Fig. 7: CBL0137 decreases the transcription of NEUROD1 and OTX2-associated genes.
From: Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
A, B Volcano plot of the normalized expression of genes in MYC-amplified medulloblastoma cells after CBL0137 treatment. Red points represent genes with P-value <0.05. C NEUROD1 expression in the MYC-amplified medulloblastoma cells which were treated with CBL0137 or DMSO was measured using RT-qPCR. D–G Enrichment plots of genes in shOTX2_48 h and shOTX2_96 h gene sets in DMSO-treated cells and CBL0137-treated cells. H ChIP-qPCR analysis of SSRP1 levels at MYC in MB cells treated with DMSO or CBL0137. The seven sites at the promoter region of NEUROD1 ware arranged up the histogram. (*P < 0.05, **P < 0.01, and ***P < 0.001).
